Ivantsov Alexandr O
N.N. Petrov Institute of Oncology, Leningradskaya 68, St.-Petersburg 197758, Russia.
Chin Clin Oncol. 2018 Dec;7(6):59. doi: 10.21037/cco.2018.09.07.
There is only a few of studies devoted to evaluation of pathologic response of ovarian cancer (OC) to neoadjuvant chemotherapy (NACT). Pathologic complete responses (pCR), which are characterized by the lack of viable tumor cells in surgical specimens, are rarely observed in ovarian carcinomas. Multiple reports demonstrate that pCR is associated with evidently improved disease outcomes. Recommendations of the International Collaboration on Cancer Reporting suggest to use recently developed Chemotherapy Response Scoring (CRS) system, which is based on the pathological analysis of surgically removed omental masses. CRS3 (complete or near-complete response) is characterized by the lack of residual tumor cells in the omentum or presence of tumor foci up to 2 mm maximum size. It is observed after NACT in approximately 30-40% patients with high-grade serous ovarian cancer (HGSOC) and is reproducibly associated with the improvement of the disease prognosis.
仅有少数研究致力于评估卵巢癌（OC）对新辅助化疗（NACT）的病理反应。病理完全缓解（pCR）的特征是手术标本中不存在存活的肿瘤细胞，在卵巢癌中很少观察到。多项报告表明，pCR与疾病结局的明显改善相关。癌症报告国际协作组织的建议是使用最近开发的化疗反应评分（CRS）系统，该系统基于对手术切除的大网膜肿块的病理分析。CRS3（完全或接近完全缓解）的特征是大网膜中不存在残留肿瘤细胞或存在最大尺寸达2 mm的肿瘤病灶。在NACT后，约30%-40%的高级别浆液性卵巢癌（HGSOC）患者中观察到CRS3，并且它与疾病预后的改善具有可重复性关联。
